Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quaternized chitosan (QCS) is a chemically modified derivative of chitosan, a natural polysaccharide derived from chitin. This modification enhances its solubility, introduces a positive charge, and often improves its inherent antibacterial properties. QCS is widely utilized as a foundational component in the development of various biomaterials, including hydrogels, nanocomposites, and wound dressings. These materials are being investigated for a broad range of biomedical applications, such as promoting wound healing in conditions like diabetic foot ulcers, oral mucosal injuries, and postoperative pancreatic fistulas, as well as for targeted drug delivery systems. Its therapeutic effects are primarily mediated through its ability to form biocompatible scaffolds, exert direct antibacterial action, modulate inflammatory responses, and stimulate tissue regeneration and angiogenesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Quaternized Chitosan.